Christopher C Blyth1, Peter Jacoby, Paul V Effler, Heath Kelly, David W Smith, Meredith L Borland, Gabriela A Willis, Avram Levy, Anthony D Keil, Peter C Richmond. 1. From the *School of Paediatrics and Child Health, University of Western Australia; †Department of Infectious Diseases, Princess Margaret Hospital for Children; ‡Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia; §Department of Microbiology, PathWest Laboratory Medicine WA, Princess Margaret Hospital for Children; ¶Department of Health, Communicable Disease Control Directorate, Perth, Western Australia, Australia; ‖Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia; **Australian National University, Canberra, Australia; ††School of Pathology and Laboratory Medicine, University of Western Australia; ‡‡Department of Microbiology, QEII Medical Centre, PathWest Laboratory Medicine WA; §§Emergency Department, Princess Margaret Hospital for Children; ¶¶School of Primary, Aboriginal and Rural Health Care, University of Western Australia; and ‖‖Department of General Paediatrics, Princess Margaret Hospital for Children, Perth, Western Australia, Australia.
Abstract
BACKGROUND: Data demonstrating the effectiveness of inactivated trivalent influenza vaccine (TIV) for children at increased risk of severe disease are limited. Our objective was to determine the effectiveness of TIV in children with risk factors for severe disease and to compare vaccine uptake, parental attitudes and prescriber recommendations in children with and without risk factors for severe disease. METHODS: Children aged 6-59 months presenting for emergency care (2008 to 2014) with an influenza-like illness were eligible. Influenza polymerase chain reaction/culture was performed on nasopharyngeal samples. Vaccination status was confirmed via the national register and/or vaccine providers. The test-negative design was used to estimate vaccine effectiveness (VE). Risk factors, parental attitudes and prescriber recommendations were assessed by parental questionnaire. RESULTS: Two thousand seven hundred twenty-three children were recruited. Risk factors for severe disease included comorbid medical conditions (11.6%), preterm birth (13.0%) and indigeneity (5.0%). Influenza was identified in 546 (20.1%) participants. Overall VE (2008 and 2010 to 2014) was 70.0% (95% confidence interval: 47.7 to 82.9); VE for children with medical comorbidities, children born preterm and children <2 years were 82.5% (14.6 to 96.4), 79.2% (10.9 to 95.1) and 84.7% (49.6 to 95.3), respectively. After adverse events in 2010, the number of children fully vaccinated with TIV declined significantly. This included children with and without risk factors for severe disease. Attitudes were similar in parents of children with and without risk factors for severe disease. CONCLUSIONS: VE for TIV in young children with and without risk factors for severe disease was ≥70%. Despite this, participation in the preschool influenza vaccination program remains low with parents and prescribers unconvinced of the benefits and safety of TIV.
BACKGROUND: Data demonstrating the effectiveness of inactivated trivalent influenza vaccine (TIV) for children at increased risk of severe disease are limited. Our objective was to determine the effectiveness of TIV in children with risk factors for severe disease and to compare vaccine uptake, parental attitudes and prescriber recommendations in children with and without risk factors for severe disease. METHODS:Children aged 6-59 months presenting for emergency care (2008 to 2014) with an influenza-like illness were eligible. Influenza polymerase chain reaction/culture was performed on nasopharyngeal samples. Vaccination status was confirmed via the national register and/or vaccine providers. The test-negative design was used to estimate vaccine effectiveness (VE). Risk factors, parental attitudes and prescriber recommendations were assessed by parental questionnaire. RESULTS: Two thousand seven hundred twenty-three children were recruited. Risk factors for severe disease included comorbid medical conditions (11.6%), preterm birth (13.0%) and indigeneity (5.0%). Influenza was identified in 546 (20.1%) participants. Overall VE (2008 and 2010 to 2014) was 70.0% (95% confidence interval: 47.7 to 82.9); VE for children with medical comorbidities, children born preterm and children <2 years were 82.5% (14.6 to 96.4), 79.2% (10.9 to 95.1) and 84.7% (49.6 to 95.3), respectively. After adverse events in 2010, the number of children fully vaccinated with TIV declined significantly. This included children with and without risk factors for severe disease. Attitudes were similar in parents of children with and without risk factors for severe disease. CONCLUSIONS: VE for TIV in young children with and without risk factors for severe disease was ≥70%. Despite this, participation in the preschool influenza vaccination program remains low with parents and prescribers unconvinced of the benefits and safety of TIV.
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Jason P Lynch; Rhiannon B Werder; Zhixuan Loh; Md Al Amin Sikder; Bodie Curren; Vivian Zhang; Matthew J Rogers; Katie Lane; Jennifer Simpson; Stuart B Mazzone; Kirsten Spann; John Hayball; Kerrilyn Diener; Mark L Everard; Christopher C Blyth; Christian Forstner; Paul G Dennis; Nida Murtaza; Mark Morrison; Páraic Ó Cuív; Ping Zhang; Ashraful Haque; Geoffrey R Hill; Peter D Sly; John W Upham; Simon Phipps Journal: J Exp Med Date: 2017-12-22 Impact factor: 14.307
Authors: Gabriela A Willis; David B Preen; Peter C Richmond; Peter Jacoby; Paul V Effler; David W Smith; Christine Robins; Meredith L Borland; Avram Levy; Anthony D Keil; Christopher C Blyth Journal: Influenza Other Respir Viruses Date: 2018-09-11 Impact factor: 4.380
Authors: Danielle Wurzel; Alissa McMinn; Monsurul Hoq; Christopher C Blyth; David Burgner; Shidan Tosif; Jim Buttery; Jeremy Carr; Julia E Clark; Allen C Cheng; Nicole Dinsmore; Joshua Reginald Francis; Anne Kynaston; Ryan Lucas; Helen Marshall; Brendan McMullan; Davinder Singh-Grewal; Nicholas Wood; Kristine Macartney; Phil N Britton; Nigel W Crawford Journal: BMJ Open Date: 2021-11-08 Impact factor: 2.692
Authors: H F Gidding; L McCallum; P Fathima; T L Snelling; B Liu; N de Klerk; C C Blyth; V Sheppeard; R M Andrews; L Jorm; P B McIntyre; H C Moore Journal: Int J Popul Data Sci Date: 2017-09-18